Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis


Terzi M.

MULTIPLE SCLEROSIS AND RELATED DISORDERS, sa.2211-0348, ss.1-4, 2023 (SCI-Expanded)